← Back
Data updated: Mar 29, 2026
HETERO LABS
DermatologyInfectious DiseaseCardiovascular
Generics
HETERO LABS is a generic drug manufacturer focused on Dermatology, Infectious Disease, Cardiovascular.
2016
Since
5
Drugs
-
Trials
53
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
LINEZOLID 2025-12-08
AMLODIPINE BESYLATE AND VALSARTAN 2025-10-15
Labeling
AMLODIPINE BESYLATE AND VALSARTAN 2025-10-15
Labeling
LINEZOLID 2025-07-03
Labeling
LINEZOLID 2025-05-23
Labeling
LINEZOLID 2025-05-23
Labeling
LINEZOLID 2025-05-23
Labeling
LINEZOLID 2025-05-23
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Dermatology 50%
2 drugs
Infectious Disease 25%
1 drugs
Cardiovascular 25%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology, Cardiovascular
COSETTE other
Cardiovascular, Dermatology, Infectious Disease
BAUSCH AND LOMB specialty
Cardiovascular, Infectious Disease, Dermatology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Cardiovascular
Active (4)
Discontinued (1)
Company Info
- First Approval
- 2016-09-16
- Latest
- 2025-05-22
- Applications
- 8
FDA Sponsor Names
HETERO LABSHETERO LABS LTD